Zynex, Inc. (NASDAQ:ZYXI) is reporting third quarter earnings results on Tuesday 27th October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 0.05 per share from $ 21.13 million in revenue.
For the full year, analysts predict revenues of $ 81.48 million, while looking forward to income of $ 0.30 per share.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 20.00 million ~ $ 20.50 million
Full Year 2020 topline are forecasted in a range of$ 80.00 million ~ $ 81.00 million
Click Here For More Historical Outlooks Of Zynex, Inc.
Previous Quarter Performance
Zynex, Inc. revealed income for the second quarter of $ 0.09 per share, from the revenue of $ 19.26 million. The quarterly earnings 50.00 percent while revenues expanded 98.56 percent compared with the same quarter last year. The top line results outshined analysts by $ 0.14 million or 0.73 percent.
Stock Performance
Shares of Zynex, Inc. traded up $ 0.23 or 1.62 percent on Friday, reaching $ 14.47 with volume of 511.50 thousand shares. Zynex, Inc. has traded high as $ 14.79 and has cracked $ 14.25 on the downward trend
According to the previous trading day, closing price of $ 14.47, representing a 89.61 % increase from the 52 week low of $ 7.51 and a 52.1 % decrease over the 52 week high of $ 29.73.
The company has a market capital of $ 502.19 million and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 14th September 2020, upgraded by HC Wainwright to Buy from Neutral rating.
Conference Call
Zynex, Inc. will be hosting a conference call at 4:15 PM eastern time on 27th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.zynex.com
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. It offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation (TENS), and neuromuscular electrical stimulation device; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and TENSWave, a dual channel TENS device. The company also distributes electrodes for the delivery of electrical current to the body; batteries for use in electrotherapy products; Comfortrac for cervical traction; JetStream for hot/cold therapy; and LSO Back Braces for lumbar support.
